PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway

Hong Sun(Howard Hughes Medical Institute), Ralf Lesche(Howard Hughes Medical Institute), Daming Li(Howard Hughes Medical Institute), Joanna Liliental(Howard Hughes Medical Institute), Hui Zhang(Howard Hughes Medical Institute), Jing Gao(Howard Hughes Medical Institute), Nadia J. Gavrilova(Howard Hughes Medical Institute), Brenda Mueller(Howard Hughes Medical Institute), Xin Liu(Howard Hughes Medical Institute), Hong Wu(Howard Hughes Medical Institute)
Proceedings of the National Academy of Sciences
May 25, 1999
Cited by 821Open Access

Abstract

To investigate the molecular basis of PTEN-mediated tumor suppression, we introduced a null mutation into the mouse Pten gene by homologous recombination in embryonic stem (ES) cells. Pten-/- ES cells exhibited an increased growth rate and proliferated even in the absence of serum. ES cells lacking PTEN function also displayed advanced entry into S phase. This accelerated G1/S transition was accompanied by down-regulation of p27(KIP1), a major inhibitor for G1 cyclin-dependent kinases. Inactivation of PTEN in ES cells and in embryonic fibroblasts resulted in elevated levels of phosphatidylinositol 3,4,5,-trisphosphate, a product of phosphatidylinositol 3 kinase. Consequently, PTEN deficiency led to dosage-dependent increases in phosphorylation and activation of Akt/protein kinase B, a well-characterized target of the phosphatidylinositol 3 kinase signaling pathway. Akt activation increased Bad phosphorylation and promoted Pten-/- cell survival. Our studies suggest that PTEN regulates the phosphatidylinositol 3,4, 5,-trisphosphate and Akt signaling pathway and consequently modulates two critical cellular processes: cell cycle progression and cell survival.


Related Papers

No related papers found

Powered by citation graph analysis